Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Depletion of αβ+ T and B Cells Using the CliniMACS Prodigy: Results of 10 Graft-Processing Procedures from Haploidentical Donors

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Male Sexual Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Multicenter Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Insulin-Like Growth Factor Gene Polymorphisms Predict Clinical Course in Allogeneic Hematopoietic Stem Cell Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Depletion of TCRαβ+ T cells and B cells with the CliniMACS Plus® has been used for haploidentical hematopoietic stem cell transplantation for a decade. The depletion procedure is time and labour demanding and with variable reported efficiencies. Recently, an automated procedure was launched for the CliniMACS Prodigy® (Miltenyi Biotec) but reported data are scarce. Here, we report the results of the first ten TCRαβ+ and B cell depletion procedures for clinical use performed at our centre.

Materials and Methods: All transplants were from a parent to a child. Collection of peripheral blood stem cells was performed after filgrastim mobilisation by use of the Spectra Optia® (TerumoBCT) set on the MNC program. Because of insufficient hematopoietic stem cell mobilisation, 1 donor received additional plerixafor.

Results: We performed ten uncomplicated processes with the CliniMACS Prodigy. We found the results of the depletion procedures satisfactory with a median log reduction of TCRαβ+ cells of -4.21 (range -3.98 to -4.74), resulting in a median number of TCRαβ+ cells in the depleted product of 28.6 × 10<sup>3</sup>/kg recipient weight (range 14.9-69.7 × 10<sup>3</sup>/kg). The median CD34 recovery was 83% (range 70-100). To achieve a sufficient number of CD34+ cells, we performed an additional CD34+ enrichment procedure using the CliniMACS Plus for 3 patients. The B cell depletion was slightly less efficient with a median log reduction of -3.72 (range -2.83 to -4.20).

Conclusion: Overall, we found the TCRαβ and CD19 depletion procedure on the CliniMACS Prodigy easy to handle and reliable, providing reproducible good results.

Original languageEnglish
JournalTransfusion Medicine and Hemotherapy (Print Edition)
Volume46
Issue number6
Pages (from-to)446-449
Number of pages4
ISSN1660-3796
DOIs
Publication statusPublished - 2019

ID: 58993119